[Form 4] CLOROX CO /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Clorox insider transaction: The company's EVP & Chief Financial Officer received 2,581 shares upon settlement of a 2022 Performance Unit Grant that vested on 10/03/2025 at a reported per-share value of $122.25. The filing shows two share-withholdings to satisfy tax obligations: 421 shares withheld for restricted stock taxes and 893 shares withheld for performance stock unit taxes. After these transactions, the reporting person beneficially owned 20,864 shares (which includes 167 dividend-reinvestment shares).

Positive

• 2,581 shares received from settlement of a 2022 Performance Unit Grant
• Beneficial ownership remains aligned at 20,864 shares, including dividend reinvestment

Negative

• 1,314 shares withheld (421 + 893) to satisfy tax obligations, reducing net share increase
• Net holdings decreased from pre-transaction levels to 20,864 shares

Insights

Compensation & Equity Specialist

Executive received vested performance units; tax withholdings reduced net share gain.

The filing records settlement of a 2022 Performance Unit Grant with 2,581 shares delivered on 10/03/2025, valued at $122.25 per share in the report. Net share additions were offset by company withholding of 421 and 893 shares to cover tax obligations tied to restricted stock and performance stock units.

This pattern is consistent with standard executive compensation mechanics where vested equity converts to stock and the issuer withholds shares for taxes. Watch upcoming filings for further vesting events or planned sales within the reporting person's trading windows over the next 12 months.

Corporate Governance Advisor

Transaction is routine and disclosed under Section 16; no unusual trading type is reported.

The Form 4 indicates normal vesting and internal tax withholding rather than open-market sales or transfers to related parties. Beneficial ownership after the transaction is reported as 20,864 shares, including 167 dividend reinvestment shares, suggesting continued equity alignment with shareholders.

Governance monitoring should note if future filings show sales beyond tax withholdings or any use of a Rule 10b5-1 plan; check subsequent Forms within the next fiscal quarter for material changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellet Luc

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CA 94612-1888

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP - Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		A(1)		2,581	A	$122.25	22,178	D
Common Stock	10/03/2025		F(2)		421	D	$122.25	21,757	D
Common Stock	10/03/2025		F(3)		893	D	$122.25	20,864(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Settlement of 2022 Performance Unit Grant, which vested 10/3/25.

2. Withholding of shares by the Company to satisfy tax obligations relating to vesting of restricted stock.

3. Withholding of shares by the Company to satisfy tax obligations relating to vesting of performance stock units.

4. Includes 167 shares acquired pursuant to a dividend reinvestment feature of the Company's Stock Incentive Plan.

	By Jinho Joo, Attorney-in-Fact for	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the CLX Form 4 filed for the CFO report on 10/03/2025?

Settlement of a 2022 Performance Unit Grant resulting in 2,581 shares delivered, with tax-withholding of 421 and 893 shares.

How many shares does the reporting person own after the reported transactions (CLX)?

The reporting person beneficially owned 20,864 shares following the transactions, which includes 167 shares from dividend reinvestment.

What price per share is shown on the Form 4 for the transactions?

The filing reports a per-share price of $122.25 for the reported transactions.

Were any shares sold on the open market according to this Form 4 for CLX?

No open-market sales are reported; the movements reflect a settlement of vested awards and company tax-withholding.

Do the filings indicate use of a Rule 10b5-1 trading plan for these transactions?

No indication of a Rule 10b5-1 plan is checked or stated for these specific transactions.